Kura Oncology, Inc. (KURA)
NASDAQ: KURA · IEX Real-Time Price · USD
21.01
+0.38 (1.84%)
May 6, 2024, 4:00 PM EDT - Market closed
Kura Oncology Employees
Kura Oncology had 142 employees on December 31, 2023. The number of employees increased by 9 or 6.77% compared to the previous year.
Employees
142
Change (1Y)
9
Growth (1Y)
6.77%
Revenue / Employee
n/a
Profits / Employee
-$1,183,711
Market Cap
1.60B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 142 | 9 | 6.77% |
Dec 31, 2022 | 133 | 12 | 9.92% |
Dec 31, 2021 | 121 | 32 | 35.96% |
Dec 31, 2020 | 89 | 29 | 48.33% |
Dec 31, 2019 | 60 | 14 | 30.43% |
Dec 31, 2018 | 46 | 14 | 43.75% |
Dec 31, 2017 | 32 | 7 | 28.00% |
Dec 31, 2016 | 25 | 1 | 4.17% |
Dec 31, 2015 | 24 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
U.S. Physical Therapy | 6,720 |
Zai Lab | 2,175 |
Taro Pharmaceutical Industries | 1,554 |
NovoCure | 1,453 |
Veracyte | 815 |
ADMA Biologics | 624 |
Dynavax Technologies | 408 |
Day One Biopharmaceuticals | 155 |
KURA News
- 3 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Kura Oncology Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 11 days ago - Kura Oncology to Report First Quarter 2024 Financial Results - GlobeNewsWire
- 14 days ago - Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML - GlobeNewsWire
- 26 days ago - Kura Oncology to Participate in Stifel Targeted Oncology Forum - GlobeNewsWire
- 2 months ago - Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma - GlobeNewsWire
- 2 months ago - Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia - GlobeNewsWire